#United Kingdom #Sobi #Glasgow #pegcetacoplan #ERA 2026

New Insights into Pegcetacoplan at ERA 2026

Introduction

Sobi® has recently announced the presentation of significant findings from its pegcetacoplan clinical development program, particularly focusing on C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN). This important research will be highlighted at the 63rd Congress of the European Renal Association (ERA), scheduled from June 3rd to 6th, 2026, in Glasgow, UK. The event promises to be a vital platform for advancing knowledge in renal diseases, with promising data stemming from the collaboration with Apellis Pharmaceuticals, currently integrated with Biogen.

Key Data Highlights

During the ERA 2026, Sobi will present crucial analyses derived from the pivotal Phase 3 VALIANT study and its long-term extension, VALE study. These studies evaluate the efficacy of pegcetacoplan in treating patients diagnosed with C3G and primary IC-MPGN. Key elements of the discussions will cover treatment responses, disease chronicity, long-term clinical benefits, as well as safety and tolerability outcomes associated with pegcetacoplan.

Dr. Lydia Abad-Franch, MD, who leads Research and Development and Medical Affairs at Sobi, emphasized the urgency of deepening the understanding of these rare and severe kidney conditions, stating, "The data being presented at ERA 2026 continues to build the evidence supporting the sustained efficacy and well-characterized safety profile of pegcetacoplan."

The presentations will explore:

• - Sustained Clinical Benefits: Evaluating the sustained clinical benefits observed through a year of therapy with pegcetacoplan.
• - Treatment Responses: Analyzing the impact of genetic and acquired complement dysregulation in the treatment responses of C3G and primary IC-MPGN patients.
• - Real-world Clinical Profiles: Insights garnered from the UK RaDaR registry, discussing treatment patterns and outcomes connected to the diseases.

Oral and Poster Presentations

The insight into pegcetacoplan will be conveyed through various oral presentations scheduled during the congress:

• - Sustained Clinical Benefit in C3G and primary IC-MPGN: Understanding the long-term benefits in patients over a year of therapy (Session FC6, June 4, 2026).
• - Impact of Disease Chronicity: Evaluation focused on treatment responses concerning diseases’ chronicity (Session Glomerular Tubulo-Interstitial Diseases, June 4, 2026).
• - Safety Profile: Details on the low incidence of meningococcal infections associated with pegcetacoplan treatments (Session Glomerular Tubulo-Interstitial Diseases, June 4, 2026).

In addition to oral presentations, there will be poster discussions highlighting epidemiology relevant to C3G and primary IC-MPGN, including systematic literature reviews and pharmacokinetics analyses among the affected populations.

Understanding C3 Glomerulopathy and IC-MPGN

C3 glomerulopathy and primary IC-MPGN are rare conditions causing significant kidney issues, potentially culminating in kidney failure. The diseases are marked by excessive C3 deposits, leading to inflammation and damage, with around 50% of patients facing kidney failure within five to ten years post-diagnosis. This creates a substantial requirement for patients needing kidney transplantation or dialysis, making ongoing research and effective therapies like pegcetacoplan critical.

Clinical Trials Overview

The VALIANT Phase 3 study, a randomized controlled trial, evaluates pegcetacoplan's safety and efficacy in patients aged 12 and older diagnosed with C3G or primary IC-MPGN. With a substantial cohort of 124 participants, it has become the largest trial conducted in these patient populations. Following an initial 26-week randomized period, patients were transitioned into a 26-week open-label phase, where all received pegcetacoplan, underscoring the commitment to understanding and mitigating the impact of these rare kidney diseases.

Conclusion

The ongoing collaboration between Sobi and Apellis underscores an essential commitment to developing targeted therapies to combat C3G and primary IC-MPGN. With groundbreaking findings set to be presented at ERA 2026, stakeholders from various medical fields will gain invaluable insights into the treatment landscape, enhancing the understanding of these conditions and ultimately optimizing patient outcomes.

For further details on the upcoming presentations and findings, follow Sobi’s news updates during the congress period.

• ---

This article encapsulates the essence of Sobi's commitment to advancing treatments for rare kidney diseases, reinforcing its position as a leader in biopharmaceutical innovation. For more updates, stay tuned as we cover more from the ERA 2026 conference.